ArticleBMJ open2025
CannChange: a protocol for a feasibility study using fMRI-based neurofeedback to change the neurobiology of craving in cannabis use disorder.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- What Do Thirty Years of Neuroimaging Research Tell Us About Recreational Cannabis Use and Brain Integrity? A Narrative Review of the Multimodal Neuroimaging Evidence to Date.Substance abuse and rehabilitation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCannabis use disorder (CUD) affects ∼33 million people globally and can be underscored by intense cravings to use cannabis, which can trigger compulsive use and relapse. Functional MRI (fMRI) evidence demonstrates hyperactivity of addiction brain pathways during cannabis cue-reactivity, consistent with prominent neuroscientific theories of addiction, particularly within the anterior cingulate cortex (ACC). The ACC also emerges as a key region of real-time fMRI-based neurofeedback (fMRI-neurofeedback) studies demonstrating voluntary changes during cravings in persons who use substances. However, this notion is untested in CUD. METHODS AND ANALYSIS: We aim to develop a protocol that tests the feasibility of fMRI-neurofeedback to enable persons with a moderate-to-severe CUD to increase the activity of the ACC during cannabis-induced craving to provide mechanistic insights on treatment targets; and decrease ACC activity during cue-induced craving to pave the way for reducing brain reactivity. The primary outcome measure is the change in ACC activity during fMRI-neurofeedback compared with a non-regulation condition. ETHICS AND DISSEMINATION: This feasibility study has been approved by the Human Research Ethics Committee of Australian Catholic University. On completion, the findings from this study will be published in academic journals, presented at conferences and disseminated to clinicians and to individuals who use cannabis. The results from this feasibility study have the potential to inform the conduct of powered trials to examine how fMRI-neurofeedback can identify and reduce craving-related brain dysfunction in CUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.